| Abatacept: a novel therapy approved for the treatment of patients with rheumatoid arthritis. | |
| | |
MedLine Citation:
|
PMID: 17565924 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
An enhanced understanding of the immunopathology of rheumatoid arthritis (RA) has led to the development of novel therapies that target specific events occurring in the immune cascade that underlies the disease. In December 2005, abatacept became the first therapy to be approved by the US Food and Drug Administration for the treatment of adult patients with moderately to severely active RA who have exhibited an inadequate response to traditional disease-modifying antirheumatic drugs or tumor necrosis factor antagonists. This article summarizes the characteristics and clinical profile of abatacept. Abatacept is a fully human soluble recombinant fusion protein that acts by binding to CD80/CD86 on antigen-presenting cells and inhibiting interaction with CD28 on T cells, thus preventing one of the co-stimulatory signals needed for full T-cell activation. It is indicated for reducing signs and symptoms of the disorder, inducing a major clinical response, slowing the progression of structural damage, and improving physical function in this patient population. Data on abatacept compiled to date demonstrate significant efficacy, combined with a consistent safety profile and tolerability, in a wide range of patients with RA, including those with an inadequate response to methotrexate or to tumor necrosis factor antagonists. |
| | |
Authors:
|
Lisa Lundquist |
Related Documents
:
|
18199544 - The adenocarcinoma-associated antigen, agr2, promotes tumor growth, cell migration, and... 2686854 - Activation of the k-ras oncogene in liver tumors of hudson river tomcod. 15833854 - Inhibition of mammalian target of rapamycin reverses alveolar epithelial neoplasia indu... 12226664 - Loss of the lkb1 tumour suppressor provokes intestinal polyposis but resistance to tran... 8516614 - Molecular basis of tumor progression: mechanisms of organ-specific tumor metastasis. 14508064 - Growth promotion of hepg2 hepatoma cells by antisense-mediated knockdown of glypican-3 ... |
Publication Detail:
|
Type: Journal Article; Research Support, Non-U.S. Gov't; Review |
Journal Detail:
|
Title: Advances in therapy Volume: 24 ISSN: 0741-238X ISO Abbreviation: Adv Ther Publication Date: 2007 Mar-Apr |
Date Detail:
|
Created Date: 2007-06-13 Completed Date: 2007-07-31 Revised Date: 2013-05-24 |
Medline Journal Info:
|
Nlm Unique ID: 8611864 Medline TA: Adv Ther Country: United States |
Other Details:
|
Languages: eng Pagination: 333-45 Citation Subset: T |
Affiliation:
|
Mercer University College of Pharmacy and Health Science, Atlanta, GA 30341, USA. lundquist_lm@mercer.edu |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Antigens, CD28
/
metabolism Antigens, CD80 / metabolism Antigens, CD86 / metabolism Antirheumatic Agents / adverse effects, pharmacokinetics, therapeutic use* Arthritis, Rheumatoid / drug therapy*, immunology Clinical Trials, Phase II as Topic Clinical Trials, Phase III as Topic Humans Immunoconjugates / adverse effects, pharmacokinetics, therapeutic use* Randomized Controlled Trials as Topic T-Lymphocytes / metabolism |
| Chemical | |
Reg. No./Substance:
|
0/Antigens, CD28; 0/Antigens, CD80; 0/Antigens, CD86; 0/Antirheumatic Agents; 0/Immunoconjugates; 7D0YB67S97/abatacept |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Effects of hyperbaric oxygen therapy on distraction osteogenesis.
Next Document: Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood press...